Tang Capital Management’s Viking Therapeutics VKTX Stock Holding History

Tang Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.5M	Hold	500,000	–	–	0.89%	26
2026 Q1	$16.3M	Hold	500,000	–	–	0.83%	26
2025 Q4	$17.6M	Sell	500,000 -370,000	-43%	-$13.1M	0.87%	26
2025 Q3	$22.9M	Buy	870,000 +500,000	+135%	+$14.9M	0.88%	33
2025 Q2	$9.8M	Buy	370,000 +100,000	+37%	+$2.63M	0.5%	52
2025 Q1	$6.52M	Sell	270,000 -50,000	-16%	-$1.58M	0.36%	64
2024 Q4	$12.9M	Buy	320,000 +200,000	+167%	+$11.4M	0.85%	32
2024 Q3	$7.6M	Hold	120,000	–	–	0.54%	55
2024 Q2	$6.36M	Buy	120,000 +20,000	+20%	+$1.31M	0.65%	48
2024 Q1	$8.2M	Buy	+100,000	New	+$4.45M	0.85%	39

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Tang Capital Management's VKTX Position: Q2 2026 in Review

Tang Capital Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 500,000 shares worth $19.5M. The position accounts for 0.89% of the portfolio, ranked #26.

Tang Capital Management first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $22.9M in Q3 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Tang Capital Management held 500,000 shares of Viking Therapeutics worth $19.5M as of Q2 2026.
Tang Capital Management left its Viking Therapeutics share count unchanged in Q2 2026.
Viking Therapeutics made up 0.89% of Tang Capital Management's portfolio in Q2 2026, its #26 holding.
Tang Capital Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
Tang Capital Management's Viking Therapeutics position peaked at $22.9M in Q3 2025.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.